Virax Biolabs (VRAX)

• Market cap: $2.97M
• 1 day: 2.37%
• 5 days: -26.79%
• 1 month: -1.58%
• 3 months: -23.84%
• 6 months: -52.72%
• Year to date: -79.46%
• 1 year: -71.81%
• 5 years: -99.75%
• 10 years: -99.75%
• Sector: Healthcare
• Industry: Biotechnology

About: Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

Employees: 19